热门资讯> 正文
Matinas BioPharma获得2027年恢复纽约证券交易所美国上市合规性的窗口期
2026-09-05 05:16
- Matinas BioPharma Holdings (MTNB) announced on Friday that it received a non-compliant notice from NYSE American for falling below its stockholders’ equity requirement.
- The company had $1.8M in stockholders’ equity as of June 30, below the required $2.0M, and has reported losses in each of its past five fiscal years.
- NYSE American has given the company until October 2, 2027, to regain compliance under its existing plan.
- The notice has no immediate impact on the stock’s listing or the company’s operations. However, failure to regain compliance could lead to delisting proceedings.
More on Matinas Biopharma
- GH Power, Matinas BioPharma join forces to create NYSE-listed clean energy company
- Matinas BioPharma faces NYSE notice over equity shortfall; gets until 2027 to comply
- Historical earnings data for Matinas Biopharma
- Financial information for Matinas Biopharma
推荐文章
今夜加息概率升破92%！全球风暴即将来袭？复盘近三轮加息周期，这次会走2015还是2022年剧本？
5%美债收益率风暴来袭！再融资炸弹倒计时开启，谁会是第一个牺牲品？
美参议院加密市场结构法案程序性投票未获通过 两党谈判破裂致立法进程受阻
利率决议前夕黄金“抢跑”！美联储两难困境正被看穿：加息是利空出尽，不加息金价冲5000？
扎克伯格称更青睐依靠评估人员确保AI安全 而非放缓发展
华盛早报 | 香港首份五年规划+26年施政报告今日公布！加密货币《清晰法案》遭否；OpenAI再融资：估值已达1.2万亿美元
携程2026Q2净利润同比下降，受处罚费用影响，录得净亏损24亿元！
加密货币法案折戟美国参议院！比特币、以太币跌至6月来最低
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
